Equities

E-Therapeutics PLC

E-Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)11.00
  • Today's Change-0.150 / -1.35%
  • Shares traded169.64k
  • 1 Year change-25.17%
  • Beta-0.1828
Data delayed at least 20 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

  • Revenue in GBP (TTM)475.00k
  • Net income in GBP-8.27m
  • Incorporated2001
  • Employees38.00
  • Location
    E-Therapeutics PLCFloor 44 Kingdom Street, Paddington CentralLONDON W2 6BDUnited KingdomGBR
  • Phone+44 204 551 8888
  • Fax+44 199 388 0207
  • Websitehttps://www.etherapeutics.co.uk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arecor Therapeutics PLC3.38m-9.42m42.11m51.00--3.19--12.46-0.3108-0.31080.11140.43140.1805--0.751666,254.90-50.32---66.40-------278.81--2.28--0.0125--107.51---50.11------
Venture Life Group PLC48.57m-756.00k46.49m153.00--0.62897.740.9571-0.0066-0.00660.36350.58440.43632.473.78317,477.10-0.6791.75-0.75722.0138.5640.30-1.564.411.551.370.23750.0034.2422.33-78.35--37.59--
Poolbeg Pharma PLC0.00-4.89m48.25m12.00--2.91-----0.0098-0.00980.000.03310.00----0.00-25.02---25.91--------------0.00-------100.60------
Celadon Pharmaceuticals PLC20.74k-8.06m52.97m----16.90--2,554.12-0.1306-0.13060.00030.04880.0016267.850.0248---64.68---71.16---29,080.42---40,384.18--1.84-12.450.6052--------------
Eco Animal Health Group Plc88.46m-1.62m56.91m228.00--0.697823.610.6433-0.024-0.0241.311.200.76641.923.41387,986.80-0.19496.03-0.26458.0243.0546.41-0.25447.892.261.220.043755.723.794.89246.94-35.90-4.43--
e-Therapeutics plc475.00k-8.27m65.15m38.00--1.96--137.17-0.0154-0.01540.00090.05680.0148--1.9212,500.00-25.79-33.25-27.10-35.11100.00100.00-1,741.90-1,490.90----0.0089---0.4193---2.53--24.22--
Redx Pharma PLC4.20m-33.16m72.93m101.00--18.72--17.36-0.099-0.0990.01260.010.0954--135.5541,603.96-75.26-52.99-166.19-88.10-----789.05-206.66----0.8405---77.52100.71-84.15--8.12--
Scancell Holdings Plc0.00-11.32m95.10m51.00---------0.0138-0.01380.00-0.01020.00----0.00-37.31-33.32-40.52-35.82-------817.98----1.73-------161.24--77.85--
Faron Pharmaceuticals Oy0.00-26.51m96.33m40.00---------0.4095-0.40950.00-0.21710.00-------287.97-213.06---963.12-----------12.02---------7.71---16.05--
Data as of Mar 28 2024. Currency figures normalised to E-Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

11.97%Per cent of shares held by top holders
HolderShares% Held
Bank J. Safra Sarasin AG (Investment Management)as of 01 Jan 202426.10m4.47%
Schroder Investment Management Ltd.as of 01 Jan 202414.19m2.43%
Investec Wealth & Investment Ltd.as of 01 Jan 20248.51m1.46%
Fidelity Investments Canada ULCas of 01 Jan 20245.86m1.00%
IG Markets Ltd.as of 01 Jan 20245.03m0.86%
Hargreaves Lansdown Asset Management Ltd.as of 01 Jan 20243.04m0.52%
Coutts & Co.as of 01 Jan 20242.85m0.49%
Rathbones Investment Management Ltd.as of 01 Jan 20241.83m0.31%
Cantor Fitzgerald Europeas of 01 Jan 20241.63m0.28%
Tantallon Capital Advisors Pte Ltd.as of 01 Jan 2024891.55k0.15%
More ▼
Data from 29 Dec 2023 - 14 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.